Skip to main content

Compare Stocks

Date Range: 

 Dicerna PharmaceuticalsPrestige Consumer HealthcareZentalis PharmaceuticalsCryoportMadrigal Pharmaceuticals
SymbolNASDAQ:DRNANYSE:PBHNASDAQ:ZNTLNASDAQ:CYRXNASDAQ:MDGL
Price Information
Current Price$26.06$49.42$54.45$49.80$134.00
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score2.01.61.61.71.7
Analysis Score4.53.32.53.53.4
Community Score3.02.83.32.72.8
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.71.72.5
Earnings & Valuation Score0.61.90.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$42.29$89.60$62.60$72.57$169.20
% Upside from Price Target62.26% upside81.30% upside14.97% upside45.73% upside26.27% upside
Trade Information
Market Cap$2.00 billion$2.47 billion$2.25 billion$2.27 billion$2.22 billion
Beta1.330.76N/A1.231.19
Average Volume788,971487,705296,454592,985160,974
Sales & Book Value
Annual Revenue$23.90 million$963.01 millionN/A$33.94 millionN/A
Price / Sales83.852.56N/A67.03N/A
CashflowN/A$4.80 per shareN/AN/AN/A
Price / CashN/A10.29N/AN/AN/A
Book Value$2.22 per share$23.30 per shareN/A$3.52 per share$27.00 per share
Price / Book11.742.12N/A14.15N/A
Profitability
Net Income$-120,460,000.00$142.28 millionN/A$-18,330,000.00$-83,950,000.00
EPS($1.76)$2.96N/A($0.55)($5.45)
Trailing P/E RatioN/A15.350.00N/AN/A
Forward P/E RatioN/A15.07N/A4,980.00N/A
P/E GrowthN/A2.96N/AN/AN/A
Net Margins-88.81%17.03%N/A-55.87%N/A
Return on Equity (ROE)-71.72%13.76%N/A-17.68%-47.64%
Return on Assets (ROA)-16.60%4.80%N/A-11.32%-43.21%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A1.22%N/A0.93%N/A
Current Ratio2.62%1.98%N/A16.13%6.84%
Quick Ratio2.62%1.14%N/A16.09%6.84%
Ownership Information
Institutional Ownership Percentage80.64%N/A67.13%88.29%74.24%
Insider Ownership Percentage11.30%1.20%N/A11.50%41.89%
Miscellaneous
Employees30252012460542
Shares Outstanding76.90 million49.91 million41.31 million45.68 million16.59 million
Next Earnings Date8/5/2021 (Estimated)8/5/2021 (Estimated)5/21/2021 (Estimated)8/5/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $193.00Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $193.00
americanbankingnews.com - May 17 at 8:30 AM
Madrigal Pharmaceuticals (NASDAQ:MDGL) PT Raised to $193.00 at Canaccord GenuityMadrigal Pharmaceuticals (NASDAQ:MDGL) PT Raised to $193.00 at Canaccord Genuity
marketbeat.com - May 17 at 7:30 AM
Chardan Capital Stick to Their Buy Rating for Madrigal Pharmaceuticals IncChardan Capital Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
investing.com - May 10 at 4:04 PM
Madrigal Pharmaceuticals (NASDAQ:MDGL) Announces Quarterly  Earnings ResultsMadrigal Pharmaceuticals (NASDAQ:MDGL) Announces Quarterly Earnings Results
americanbankingnews.com - May 9 at 1:16 PM
Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals IncLeerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
investing.com - May 9 at 9:24 AM
-$3.75 EPS Expected for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) This Quarter-$3.75 EPS Expected for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) This Quarter
americanbankingnews.com - May 8 at 9:14 AM
Madrigal: Q1 Earnings SnapshotMadrigal: Q1 Earnings Snapshot
sfgate.com - May 6 at 11:53 AM
Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights
finance.yahoo.com - May 6 at 11:53 AM
Madrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High at $137.81Madrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High at $137.81
americanbankingnews.com - April 27 at 1:38 PM
Were Keeping An Eye On Madrigal Pharmaceuticals (NASDAQ:MDGL) Cash Burn RateWe're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
nasdaq.com - April 27 at 8:41 AM
MDGL Makes Notable Cross Below Critical Moving AverageMDGL Makes Notable Cross Below Critical Moving Average
nasdaq.com - March 23 at 5:42 PM
Madrigal Pharmaceuticals, Inc.(MDGL)Madrigal Pharmaceuticals, Inc.(MDGL)
fool.com - March 11 at 9:27 AM
Leerink Partners Maintains Their Buy Rating on Madrigal Pharmaceuticals (MDGL)Leerink Partners Maintains Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
smarteranalyst.com - March 2 at 12:35 PM
Madrigal: 4Q Earnings Snapshot | Raleigh News & ObserverMadrigal: 4Q Earnings Snapshot | Raleigh News & Observer
newsobserver.com - February 25 at 7:22 AM
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
finance.yahoo.com - February 25 at 7:22 AM
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
finance.yahoo.com - February 25 at 7:22 AM
Market insanity hits MicroCapMarket insanity hits MicroCap
fxstreet.com - February 5 at 10:14 AM
The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomets Spin-Off, IPO Deluge Hits StreetThe Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street
msn.com - February 5 at 10:14 AM
Is MDGL A Good Stock To Buy Now?Is MDGL A Good Stock To Buy Now?
finance.yahoo.com - December 17 at 12:30 AM
Heres Why Were Not Too Worried About Madrigal Pharmaceuticals (NASDAQ:MDGL) Cash Burn SituationHere's Why We're Not Too Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation
finance.yahoo.com - November 24 at 12:09 PM
MDGL Nov 2020 110.000 callMDGL Nov 2020 110.000 call
uk.finance.yahoo.com - November 21 at 8:03 PM
MDGL Nov 2020 80.000 callMDGL Nov 2020 80.000 call
uk.finance.yahoo.com - November 20 at 10:43 PM
MDGL Nov 2020 155.000 callMDGL Nov 2020 155.000 call
uk.finance.yahoo.com - November 20 at 5:41 PM
Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- SlideshowMadrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow
seekingalpha.com - November 19 at 8:15 PM
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The ...Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The ...
apnews.com - November 14 at 1:45 PM
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 TrialMadrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
finance.yahoo.com - November 13 at 10:06 AM
DateCompanyBrokerageAction
4/22/2021Dicerna PharmaceuticalsThe Goldman Sachs GroupInitiated Coverage
4/19/2021Dicerna PharmaceuticalsTruist SecuritiesBoost Price Target
4/13/2021Dicerna PharmaceuticalsSVB LeerinkLower Price Target
3/8/2021Dicerna PharmaceuticalsChardan CapitalBoost Price Target
3/8/2021Dicerna PharmaceuticalsHC WainwrightBoost Price Target
3/1/2021Dicerna PharmaceuticalsB. RileyBoost Price Target
5/12/2020Dicerna PharmaceuticalsRoyal Bank of CanadaInitiated Coverage
5/11/2020Dicerna PharmaceuticalsSunTrust BanksBoost Price Target
5/17/2021Prestige Consumer HealthcareDA DavidsonBoost Price Target
12/2/2020Prestige Consumer HealthcareBMO Capital MarketsUpgrade
11/9/2020Prestige Consumer HealthcareCIBCBoost Price Target
11/6/2020Prestige Consumer HealthcareTD SecuritiesBoost Price Target
6/29/2020Prestige Consumer HealthcareSidotiUpgrade
6/17/2020Prestige Consumer HealthcareOppenheimerReiterated Rating
4/14/2020Prestige Consumer HealthcareJefferies Financial GroupDowngrade
1/19/2021Zentalis PharmaceuticalsWedbushInitiated Coverage
12/16/2020Zentalis PharmaceuticalsMorgan StanleyBoost Price Target
9/28/2020Zentalis PharmaceuticalsCantor FitzgeraldInitiated Coverage
4/28/2020Zentalis PharmaceuticalsGuggenheimInitiated Coverage
5/11/2021CryoportNeedham & Company LLCBoost Price Target
3/22/2021CryoportUBS GroupInitiated Coverage
1/19/2021CryoportKeyCorpBoost Price Target
1/14/2021CryoportRoth CapitalBoost Price Target
8/24/2020CryoportStephensBoost Price Target
5/17/2021Madrigal PharmaceuticalsCanaccord GenuityBoost Price Target
11/23/2020Madrigal PharmaceuticalsEvercore ISIReiterated Rating
11/5/2020Madrigal PharmaceuticalsPiper SandlerLower Price Target
8/6/2020Madrigal PharmaceuticalsStifel NicolausReiterated Rating
(Data available from 5/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.